Buradasınız

Anasayfa » Content

Tedaviyle İlişkili AML-M4 Gelişen Endometrium Kanserli Bir Olgu

A Case With Treatment Related AML-M4 Developing Endometrium Cancer

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In solid organ tumors, the increasing use of alkalizing agents and topoisomerases have increased the incidence of secondary leukemia in connection with extension of the life expectancy of cancer patients. The treatment related leukemia forms 10-20% of all cases of leukemia. Our case was diagnosed with endometrium cancer in March 2008 and during follow up of sisplatin-doxorubisin-radiotherapy treatment thrombocytopenia was detected. Then upon investigation of the bone marrow material our case was diagnosed with AML M4 based on French American British (FAB) classification AML M4 and then the diagnoses was verified after molecular cytogenetic (FISH) analysis conducted on bone marrow material, since inv 16 was positive. Our patient died in a short time because of complications related to leukemia. If after treatment of primary malign tumors the hematologic conditions are monitored carefully, even for a short term, AML might be detected related to various treatments. To conclude, we consider our case to be of importance since acute leukemia has developed with inv 16 positivity within a very short period of five months after treatment, which is a case rarely observed in the literature.
Bookmark/Search this post with
Abstract (Original Language): 
Solid organ tümörlerinde alkilleyici ajanların ve topoizomerazların yaygın kullanılmaya başlanması kanser hastalarının yaşam süresinin uzamasına bağlı olarak ikincil lösemi insidansını arttırmıştır. Tedavi ilişkili lösemiler tüm lösemilerin yaklaşık %10-20 sini oluşturur. Olgumuz Mart 2008 tarihinde endometrium kanseri tanısı almış olup, sisplatin-doksorubisin-radyoterapi tedavisi sonrası takiplerinde trombositopeni saptandı. Bunun üzerine yapılan kemik iliği materyali değerlendirilmesi sonucunda French American British (FAB) sınıflamasına göre AML M4 tanısı alan olgumuzun kemik iliği materyaline yapılan moleküler sitogenetik (FISH) analizinde de inv 16 pozitif olarak bulularak tanı doğrulandı. Olgumuz, kısa sürede lösemiye bağlı komplikasyonlar nedeniyle kaybedildi. Primer malignitenin tedavisi takibinde kısa süre bile olsa hematolojik durumlar dikkatli olarak incelenirse bir çok tedavi bağımlı AML saptanabilir. Sonuç olarak, tedaviyle ilişkili akut löseminin 5 ay gibi kısa sürede gelişen ve inv 16 pozitif saptanan endometrium kanserli olgumuz, literatürde nadir görülmesi sebebiyle önem taşımaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-tedaviyle-iliskili-aml-m4-gelisen-endometrium-kanserli-bir-olgu.pdf
  • 2
105-107
  • Turkish

REFERENCES

References: 

1. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The
incidence of secondary leukemias. Haematologica.
1999 ;84:937-45
2. Mike V, Meadows AT, D’Angiò GJ. Incidence of second
malignant neoplasms in children: results of an international
study. Lancet 1982; 2:1326-31.
3. Thirmann MJ, Larson RA. Therapy-related myeloid leukemia.
Hematol Oncol Clin N Am 1996; 2:293-317.
4. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following
Hodgkin’s disease. N Engl J Med 1990; 322:7-13.
5. Haas JF, Kittelmann B, Mehnert WH, et al. Risk of leukaemia
in ovarian tumor and breast cancer patients following treatment
by cyclophosphamide. Br J Cancer 1987; 55:213-8.
6. Felix CA. Secondary leukemias induced by topoisomerasetargeted drugs. Bioch Biophys Acta 1998;1400:233-55.
7. Pedersen-Bjergaard J, Andersen MK. Secondary or therapyrelated MDS and AML and their chromosome aberrations:
important to study but difficult to establishcausality.
Haematologica 1998; 83:481-2.
8. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip
P.Different genetic pathways in leukemogenesis for patients
presenting with therapy-related myelodysplasia and therapyrelated acute myeloid leukemia. Blood 1995;86:3542-52.
9. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR,
Kobayashi H, Ziemin-van der Poel S, Kaneko Y, Morgan R,
Sandberg AA. Rearrangement of the MLL gene in acute
lymphoblastic and acute myeloid leukemias with 11q23
chromosomal translocations. N Engl J Med 1993;329:909-14.
10. Kayıran SM, Ozbek N Acute monoblastic leukemia as a second
malignancy after doxorubicin and cisplatin treatment for
osteosarcoma. Turk J Haematol 2003;20: 39-42
11. Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH,
Prince HM. Secondary acute myeloid leukemia with inv(16):
report of two cases following paclitaxel-containing
chemotherapy and review of the role of intensified ara-C
therapy. Leukemia. 1999;13:1735-40.
12. Smith RE. Risk for the development of treatment-related acute
myelocytic leukemia and myelodysplastic syndrome among
patients with breast cancer: review of the literature and the
National Surgical Adjuvant Breast and Bowel Project
experience. Clin Breast Cancer. 2003;4:273-9.
13. Chambers SK, Chopyk RL, Chambers JT, Schwartz PE, Duffy
TP. Development of leukemia after doxorubicin and cisplatin
treatment for ovarian cancer. Cancer. 1989 ;64:2459-61.
14. Zunino F, Capranico G. DNA topoisomerase II as the primary
target of anti-tumor anthracyclines. Anticancer Drug Des
1990;5:307-17.
15. Dabholkar M, Reed E. Cisplatin. Cancer Chemother Biol
Response Modif 1996;16:88-110.

Thank you for copying data from http://www.arastirmax.com